Mesenchymal stem cells as anti-inflammatories

Implications for treatment of Duchenne muscular dystrophy

Thomas E. Ichim, Doru T. Alexandrescu, Fabio Solano, Fabian Lara, Rosalia De Necochea Campion, Eugenia Paris, Erik J. Woods, Michael Murphy, Constantin A. Dasanu, Amit N. Patel, Annette M. Marleau, Alejandro Leal, Neil H. Riordan

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Duchenne muscular dystrophy (DMD) is a lethal X-linked musculodegenerative condition consisting of an underlying genetic defect whose manifestation is augmented by inflammatory mechanisms. Previous treatment approaches using gene replacement, exon-skipping or allogeneic cell therapy have been relatively unsuccessful. The only intervention to mediate improvement in survival, albeit minor, is glucocorticoid treatment. Given this modality appears to function via suppression of underlying inflammation; we focus this review on the inflammatory response as a target for mesenchymal stem cell (MSC) therapy. In contrast to other cell based therapies attempted in DMD, MSC have the advantages of (a) ability to fuse with and genetically complement dystrophic muscle; (b) possess anti-inflammatory activities; and (c) produce trophic factors that may augment activity of endogenous repair cells. We conclude by describing one practical scenario of stem cell therapy for DMD.

Original languageEnglish
Pages (from-to)75-82
Number of pages8
JournalCellular Immunology
Volume260
Issue number2
DOIs
StatePublished - 2010

Fingerprint

Duchenne Muscular Dystrophy
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Anti-Inflammatory Agents
Therapeutics
Glucocorticoids
Exons
Stem Cells
Inflammation
Muscles
Genes

Keywords

  • Cord blood stem cells
  • Duchenne muscular dystrophy
  • Endometrial regenerative cells
  • Immune modulation
  • Inflammation
  • Mesenchymal stem cells
  • Regenerative medicine
  • Stem cell therapy
  • T regulatory cells

ASJC Scopus subject areas

  • Immunology

Cite this

Ichim, T. E., Alexandrescu, D. T., Solano, F., Lara, F., Campion, R. D. N., Paris, E., ... Riordan, N. H. (2010). Mesenchymal stem cells as anti-inflammatories: Implications for treatment of Duchenne muscular dystrophy. Cellular Immunology, 260(2), 75-82. https://doi.org/10.1016/j.cellimm.2009.10.006

Mesenchymal stem cells as anti-inflammatories : Implications for treatment of Duchenne muscular dystrophy. / Ichim, Thomas E.; Alexandrescu, Doru T.; Solano, Fabio; Lara, Fabian; Campion, Rosalia De Necochea; Paris, Eugenia; Woods, Erik J.; Murphy, Michael; Dasanu, Constantin A.; Patel, Amit N.; Marleau, Annette M.; Leal, Alejandro; Riordan, Neil H.

In: Cellular Immunology, Vol. 260, No. 2, 2010, p. 75-82.

Research output: Contribution to journalArticle

Ichim, TE, Alexandrescu, DT, Solano, F, Lara, F, Campion, RDN, Paris, E, Woods, EJ, Murphy, M, Dasanu, CA, Patel, AN, Marleau, AM, Leal, A & Riordan, NH 2010, 'Mesenchymal stem cells as anti-inflammatories: Implications for treatment of Duchenne muscular dystrophy', Cellular Immunology, vol. 260, no. 2, pp. 75-82. https://doi.org/10.1016/j.cellimm.2009.10.006
Ichim, Thomas E. ; Alexandrescu, Doru T. ; Solano, Fabio ; Lara, Fabian ; Campion, Rosalia De Necochea ; Paris, Eugenia ; Woods, Erik J. ; Murphy, Michael ; Dasanu, Constantin A. ; Patel, Amit N. ; Marleau, Annette M. ; Leal, Alejandro ; Riordan, Neil H. / Mesenchymal stem cells as anti-inflammatories : Implications for treatment of Duchenne muscular dystrophy. In: Cellular Immunology. 2010 ; Vol. 260, No. 2. pp. 75-82.
@article{2698aa3aeb824b938e9e9dda061228b1,
title = "Mesenchymal stem cells as anti-inflammatories: Implications for treatment of Duchenne muscular dystrophy",
abstract = "Duchenne muscular dystrophy (DMD) is a lethal X-linked musculodegenerative condition consisting of an underlying genetic defect whose manifestation is augmented by inflammatory mechanisms. Previous treatment approaches using gene replacement, exon-skipping or allogeneic cell therapy have been relatively unsuccessful. The only intervention to mediate improvement in survival, albeit minor, is glucocorticoid treatment. Given this modality appears to function via suppression of underlying inflammation; we focus this review on the inflammatory response as a target for mesenchymal stem cell (MSC) therapy. In contrast to other cell based therapies attempted in DMD, MSC have the advantages of (a) ability to fuse with and genetically complement dystrophic muscle; (b) possess anti-inflammatory activities; and (c) produce trophic factors that may augment activity of endogenous repair cells. We conclude by describing one practical scenario of stem cell therapy for DMD.",
keywords = "Cord blood stem cells, Duchenne muscular dystrophy, Endometrial regenerative cells, Immune modulation, Inflammation, Mesenchymal stem cells, Regenerative medicine, Stem cell therapy, T regulatory cells",
author = "Ichim, {Thomas E.} and Alexandrescu, {Doru T.} and Fabio Solano and Fabian Lara and Campion, {Rosalia De Necochea} and Eugenia Paris and Woods, {Erik J.} and Michael Murphy and Dasanu, {Constantin A.} and Patel, {Amit N.} and Marleau, {Annette M.} and Alejandro Leal and Riordan, {Neil H.}",
year = "2010",
doi = "10.1016/j.cellimm.2009.10.006",
language = "English",
volume = "260",
pages = "75--82",
journal = "Cellular Immunology",
issn = "0008-8749",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Mesenchymal stem cells as anti-inflammatories

T2 - Implications for treatment of Duchenne muscular dystrophy

AU - Ichim, Thomas E.

AU - Alexandrescu, Doru T.

AU - Solano, Fabio

AU - Lara, Fabian

AU - Campion, Rosalia De Necochea

AU - Paris, Eugenia

AU - Woods, Erik J.

AU - Murphy, Michael

AU - Dasanu, Constantin A.

AU - Patel, Amit N.

AU - Marleau, Annette M.

AU - Leal, Alejandro

AU - Riordan, Neil H.

PY - 2010

Y1 - 2010

N2 - Duchenne muscular dystrophy (DMD) is a lethal X-linked musculodegenerative condition consisting of an underlying genetic defect whose manifestation is augmented by inflammatory mechanisms. Previous treatment approaches using gene replacement, exon-skipping or allogeneic cell therapy have been relatively unsuccessful. The only intervention to mediate improvement in survival, albeit minor, is glucocorticoid treatment. Given this modality appears to function via suppression of underlying inflammation; we focus this review on the inflammatory response as a target for mesenchymal stem cell (MSC) therapy. In contrast to other cell based therapies attempted in DMD, MSC have the advantages of (a) ability to fuse with and genetically complement dystrophic muscle; (b) possess anti-inflammatory activities; and (c) produce trophic factors that may augment activity of endogenous repair cells. We conclude by describing one practical scenario of stem cell therapy for DMD.

AB - Duchenne muscular dystrophy (DMD) is a lethal X-linked musculodegenerative condition consisting of an underlying genetic defect whose manifestation is augmented by inflammatory mechanisms. Previous treatment approaches using gene replacement, exon-skipping or allogeneic cell therapy have been relatively unsuccessful. The only intervention to mediate improvement in survival, albeit minor, is glucocorticoid treatment. Given this modality appears to function via suppression of underlying inflammation; we focus this review on the inflammatory response as a target for mesenchymal stem cell (MSC) therapy. In contrast to other cell based therapies attempted in DMD, MSC have the advantages of (a) ability to fuse with and genetically complement dystrophic muscle; (b) possess anti-inflammatory activities; and (c) produce trophic factors that may augment activity of endogenous repair cells. We conclude by describing one practical scenario of stem cell therapy for DMD.

KW - Cord blood stem cells

KW - Duchenne muscular dystrophy

KW - Endometrial regenerative cells

KW - Immune modulation

KW - Inflammation

KW - Mesenchymal stem cells

KW - Regenerative medicine

KW - Stem cell therapy

KW - T regulatory cells

UR - http://www.scopus.com/inward/record.url?scp=71349083734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71349083734&partnerID=8YFLogxK

U2 - 10.1016/j.cellimm.2009.10.006

DO - 10.1016/j.cellimm.2009.10.006

M3 - Article

VL - 260

SP - 75

EP - 82

JO - Cellular Immunology

JF - Cellular Immunology

SN - 0008-8749

IS - 2

ER -